[go: up one dir, main page]

WO2006038107A3 - Method for inhibiting fibrogenesis by an rhdecorin-fc fusion protein - Google Patents

Method for inhibiting fibrogenesis by an rhdecorin-fc fusion protein Download PDF

Info

Publication number
WO2006038107A3
WO2006038107A3 PCT/IB2005/002999 IB2005002999W WO2006038107A3 WO 2006038107 A3 WO2006038107 A3 WO 2006038107A3 IB 2005002999 W IB2005002999 W IB 2005002999W WO 2006038107 A3 WO2006038107 A3 WO 2006038107A3
Authority
WO
WIPO (PCT)
Prior art keywords
rhdecorin
fusion protein
decorin
lifetime
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002999
Other languages
French (fr)
Other versions
WO2006038107A2 (en
Inventor
Mengsu Yang
Hsiang-Fu Kung
Yaou Zhang
Celina S M Cheng
Pik Yuen Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2005800371903A priority Critical patent/CN101115839B/en
Publication of WO2006038107A2 publication Critical patent/WO2006038107A2/en
Publication of WO2006038107A3 publication Critical patent/WO2006038107A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to methods for inhibiting liver fibrogenesis in vitro and/or in vivo with directly administered recombinant rhDecorin and rhDecorin-Fc fusion protein. In one embodiment a linker is provided between Decorin and the Fc hinge fragment to form a fusion protein which increases the biologic activity of Decorin and increases the ability to bind to TGF-ß and extends the lifetime of decorin in serum, where the Fc hinge fragment is a modified form of Fc involving the replacement of four N-terminal amino acids with ten different amino acids which extends the lifetime of the Decorin-Fc protein by 50%.
PCT/IB2005/002999 2004-08-30 2005-07-18 Method for inhibiting fibrogenesis by an rhdecorin-fc fusion protein Ceased WO2006038107A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2005800371903A CN101115839B (en) 2004-08-30 2005-07-18 Method of inhibiting fibrogenesis by rhDecorin-Fc fusion protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92915904A 2004-08-30 2004-08-30
US10/929,159 2004-08-30

Publications (2)

Publication Number Publication Date
WO2006038107A2 WO2006038107A2 (en) 2006-04-13
WO2006038107A3 true WO2006038107A3 (en) 2006-08-31

Family

ID=36142914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002999 Ceased WO2006038107A2 (en) 2004-08-30 2005-07-18 Method for inhibiting fibrogenesis by an rhdecorin-fc fusion protein

Country Status (2)

Country Link
CN (1) CN101115839B (en)
WO (1) WO2006038107A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020027026A2 (en) 2018-07-03 2021-04-06 Catalent Pharma Solutions, Llc MULTIFUNCTIONAL PROTEIN MOLECULES UNDERSTANDING DECORINATION AND USE OF THE SAME

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072100A2 (en) * 2003-02-07 2004-08-26 The Regents Of The University Of California Nell peptide expression systems and bone formation activity of nell peptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583103A (en) * 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
CN1216913C (en) * 2002-07-10 2005-08-31 清华大学 Human interleukin-17 receptor sampling molecule fusion protein and coding gene and expression cell line

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072100A2 (en) * 2003-02-07 2004-08-26 The Regents Of The University Of California Nell peptide expression systems and bone formation activity of nell peptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JONSSON M. ET AL.: "Initiation of the Decorin Glycosaminoglycan Chain in the Endoplasmic Reticulum-Golgi Intermediate Compartment", J. BIOL. CHEM., vol. 278, no. 24, 13 June 2003 (2003-06-13), pages 21415 - 21420 *

Also Published As

Publication number Publication date
WO2006038107A2 (en) 2006-04-13
CN101115839A (en) 2008-01-30
CN101115839B (en) 2011-05-04

Similar Documents

Publication Publication Date Title
WO2008052043A3 (en) Opioid receptor agonist fusion proteins
EP2540309A3 (en) Tissue protective peptides and uses thereof
WO2008043822A3 (en) Amino acid sequences that bind to a desired molecule in a conditional manner
WO2007115837B1 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
ZA200803403B (en) Botulinum neurotoxin a protein receptor and use thereof
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
ATE517922T1 (en) STABILIZED SINGLE-DOMAIN ANTIBODIES IN A PHARMACEUTICAL COMPOSITION DESIGNED FOR INHALATION
WO2004030522A3 (en) Diagnosis and monitoring of diseases
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
WO2004041865A3 (en) Stabilized single domain antibodies
WO2000032631A3 (en) Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof
WO2009004822A1 (en) ANTI-Muc17 ANTIBODY
WO2007107587A3 (en) Cholesterol lowering protein hydrolysates
WO2005087811A3 (en) Estrogen receptors and methods of use
WO2005124341A3 (en) Stable isotope labeled polypeptide standards for protein quantitation
WO2003065003A3 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
WO2002018443A3 (en) A recombinant monoclonal antibody to phosphotyrosine-containing proteins
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2009074318A3 (en) Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
ATE529445T1 (en) BIOKINETICS FOR RAPID ELIMINATION OF POLYPEPTIDES
WO2007047504A3 (en) Natriuretic peptide modified transferrin fusion proteins
WO2005000862A3 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
WO2005028615A3 (en) Methods and compositions for detecting promoter activity and expressing fusion proteins
NZ562436A (en) Toll-like receptor 14 (TLR14) and use thereof
WO2004005317A3 (en) Thrombin peptide derivative dimers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200580037190.3

Country of ref document: CN

122 Ep: pct application non-entry in european phase

Ref document number: 05787363

Country of ref document: EP

Kind code of ref document: A2